• Understanding Genetic Testing
    2025/10/28

    Join host Alisyn Camerota as she welcomes Jessica Everett, MS, CGC, Senior Research Strategy Director at UC San Diego's Moores Cancer Center, to discuss the critical role of genetic testing in pancreatic cancer. Since becoming part of the standard of care in 2018, genetic testing is now recommended for all pancreatic cancer patients.

    Jessica, a genetic counselor specializing in pancreatic cancer, explains why patients should get tested, how genetic counselors guide patients through the testing process, and addresses common fears and misconceptions. Learn how to navigate conversations with family members about inherited risk and what genetic test results mean for relatives.


    続きを読む 一部表示
    30 分
  • Learning About Pancreatic Cancer Surgery with Dr. Niraj Gusani
    2025/10/10
    Join host Alisyn Camerota as she sits down with Dr. Niraj Gusani, a board-certified surgical oncologist at Baptist MD Anderson Cancer Center in Jacksonville, Florida, to discuss the role of surgery in pancreatic cancer treatment. In this episode, we learn how doctors determine if a patient is a candidate for curative surgery, the impact of tumor location on surgical approach, and dive deep into the two main procedures: the Whipple procedure for tumors in the head of the pancreas and distal pancreatectomy for tumors in the tail. Dr. Gusani also explains why many patients receive chemotherapy before surgery and what patients can expect during recovery.Learn More: Let's Win Pancreatic CancerPanCANPanCAN's Patient ServicesThe Anatomy of a Whipple Procedure Understanding Distal Pancreatectomy Transcript:Julie Fleshman: Hi, I'm Julie Fleshman, President and CEO of PanCAN. On today's podcast, we are taking a closer look at surgery for patients who have been diagnosed with pancreatic cancer.Alisyn Camerota: Hi, everyone. I'm Alisyn Camerota. Welcome to episode seven of PancChat. Today's episode focuses on surgery for pancreatic cancer, including the Whipple procedure. We want to thank our sponsor, Revolution Medicines, and I want to introduce our guest.Dr. Niraj Gusani is a board-certified general surgeon and surgical oncologist with more than twenty years of experience in cancer surgery. He currently serves as the Chief of Surgical Oncology at Baptist MD Anderson Cancer Center in Jacksonville, Florida. So welcome, Dr. Gusani.Great to see you.Dr. Niraj Gusani: Oh, thank you, Alisyn. Great to be here.Alisyn Camerota: Okay, so as I understand it, there are a couple of different types of surgery. The first one is used to treat symptoms. In other words, inserting a stent, say, to open a blocked bile duct. And then there is the kind of surgery that tries to actually cure the patient of pancreatic cancer by removing the tumor, and that's the one that we want to be talking about today. So let's start there.Can you explain where surgery fits into pancreatic cancer treatment?Dr. Niraj Gusani: Yeah, thank you. You know, as you said, there are a lot of options at every stage for every patient to help them with symptoms, blockages, etcetera. And so palliative surgery is an important part of cancer surgery for pancreas cancer and for many other cancers. But today, let's focus a little bit more on what we call curative intent surgery. And that would be basically you have a tumor that's localized to the pancreas or the area of the pancreas, and we're trying to remove it completely, to help in the treatment of the patient with an attempt for cure.Now, it's really important to remember, surgery only works in combination with other treatments. Pancreatic cancer is not a disease surgery alone can cure. We need all patients to get a combination of treatments, usually chemotherapy and surgery in different orders, depending on the patient, and sometimes radiation as well, sometimes immunotherapy, vaccines, a lot of the newer things that we're doing for pancreatic cancer treatment.Alisyn Camerota: In my just very limited experience, my impression is that very few patients are eligible for surgery because it has to be caught at such an early stage. Is that accurate? And do you have any, can you give us any idea of what percentage of patients?Dr. Niraj Gusani: Yeah, so as you're suggesting, unfortunately, most pancreatic cancers are caught at a very late stage and we're working on early diagnosis and screening and so on. But the reality is that a lot of people are not going to be candidates for curative surgery, but a large percentage are, and we're increasing that pool by shrinking the tumors with chemotherapy, with immunotherapy, other treatments first, so we can get to surgery. I would say early on upfront, the percentage of patients who have a resectable tumor is quite small, ten or fifteen percent, but we can get that number higher with modern treatments.Alisyn Camerota: Good, I do want to talk about that, how we get there. So first off, how do you decide if a candidate is a good one for surgery?Dr. Niraj Gusani: Yeah, so it's a bunch of different things that we have to look at. So the very first thing, we start just because it's cancer, we start to know, we want to know all about the tumor. So we want to know anatomically where it lies, is it involved with the pancreas, is it involving other organs, is it involving blood vessels? God forbid, could it have spread to other organs? So we do staging, looking for signs of tumor elsewhere. So we want to know all the details about the tumor itself. Next, we want to know about the tumor biology. So is it something that is very aggressive, has been growing fast, has high tumor markers in the blood suggesting shed potentially into the blood. Those things help us determine how aggressive that tumor is, and under the microscope, we look at the pathology as well. And then finally, we look ...
    続きを読む 一部表示
    17 分
  • Clinical Trials for Pancreatic Cancer
    2025/09/08

    How do doctors decide when to use standard chemotherapy, explore immunotherapy, or recommend a clinical trial? In this episode of PancChat, host Alisyn Camerota speaks with Dr. Andrew Hendifar about how tumor sequencing, genetic testing, and emerging KRAS-targeted therapies are reshaping pancreatic cancer care. They discuss the challenges patients face navigating clinical trials, why timing and advocacy are critical, and why — despite the daunting diagnosis — there’s more reason for hope today than ever before.

    Dr. Andrew Hendifar heads the Gastrointestinal Disease Research Group and founded their Hematology and Oncology Fellowship Program at Cedars-Sinai Medical Center in Los Angeles. He works with SWOG and the NIH’s Neuroendocrine Tumor Task Force., Dr. Hendifar is a member of PanCAN’s Scientific and Medical Advisory Board.

    Learn more about how clinical trials work on the Let’s Win What Is a Clinical Trial? Page or PanCAN’s Clinical Trials page.

    You can explore available clinical trials through the Let’s Win’s Trial Finder or the PanCAN Clinical Trial Finder.

    For a personalized search, PanCAN’s Patient Services is also here to help.


    続きを読む 一部表示
    21 分
  • Treatment Options for Pancreatic Cancer
    2025/08/28

    When facing a pancreatic cancer diagnosis, patients and families are often met with difficult choices. In this episode of PancChat, host Alisyn Camerota speaks with Dr. Michael Pishvaian about what “standard of care” really means, the role of surgery, chemotherapy, and radiation, and why clinical trials remain such a critical -- yet underutilized -- option. Together, they unpack the treatment options and barriers to clinical trials.

    Dr. Michael Pishvaian is the director of Gastrointestinal, Developmental Therapeutics, and Clinical Research Programs for the Johns Hopkins Kimmel Cancer Center in the Greater Washington D.C. area and an associate professor at the School of Medicine. He is the Vice Chair of PanCAN’s Scientific and Medical Advisory Board and a member of the Let’s Win Scientific Advisory Board.

    For more information about treatments visit Let’s Win’s Treatment Options section and PanCAN’s Pancreatic Cancer Treatment page. PanCAN’s Patient Services can also provide free, personalized information about treatments.

    Sponsored by Revolution Medicines.

    続きを読む 一部表示
    25 分
  • What You Need To Know About Screening for Pancreatic Cancer
    2025/07/31

    Who should be screened for pancreatic cancer, and when should it start?


    In this episode of PancChat, host Alisyn Camerota speaks with leading experts Dr. Michael Goggins (Johns Hopkins) and Dr. Anirban Maitra (MD Anderson / NYU Langone) about identifying higher-risk individuals and creating personalized surveillance plans.

    From genetic mutations like BRCA to family history, pancreatic cysts, and new-onset diabetes — the doctors break down what puts someone at increased risk — and how that translates into screening recommendations. They discuss the importance of working with specialized centers, the role of annual MRIs and endoscopic ultrasounds, and why starting surveillance around age 50 (or earlier for some genetic conditions) can be potentially life-saving.

    Whether you have a family history, carry a genetic mutation, or are navigating risk assessment for yourself or a loved one, this episode offers expert guidance to help you make informed decisions about pancreatic cancer surveillance.

    Don’t forget to follow PancChat to get new episodes — delivered twice a month — right in your podcast feed. Available on all major platforms, wherever you get your podcasts.

    Resources:

    letswinpc.org

    pancan.org

    続きを読む 一部表示
    29 分
  • Pancreatic Cancer Risk Factors with Dr. Michael Goggins and Dr. Anirban Maitra
    2025/07/25

    In this episode of PancChat, host Alisyn Camerota is joined by Dr. Michael Goggins and Dr. Anirban Maitra for an in-depth discussion about the risk factors for pancreatic cancer. Together, explore lifestyle, inherited, and disease-related risks, explain how genetics and new-onset diabetes may signal increased vulnerability, and share proactive steps listeners can take to manage their risk.

    Whether you’re a healthcare provider, a patient, or simply interested in cancer prevention, this conversation offers valuable insights and actionable guidance for early detection and monitoring. Tune in to learn more about the latest research and resources available from Let’s Win Pancreatic Cancer and PanCAN.

    続きを読む 一部表示
    26 分
  • Pancreatic Cancer Treatments and Research with Dr. Anna Berkenblit and Dr. Allyson Ocean
    2025/07/11

    In this episode of PancChat, host Alisyn Camerota speaks with Dr. Anna Berkenblit, Chief Scientific and Medical Officer at PanCAN, and Dr. Allyson Ocean of Weill Cornell, co-founder of Let’s Win and chair of its Scientific Advisory Board.

    They discuss the current state of pancreatic cancer treatment, including promising developments in KRAS inhibitors and cancer vaccines, as well as the practical challenges patients face in accessing clinical trials.

    The conversation also explores how advocacy, research, and early detection efforts are shaping the future of care.

    For more information, visit letswinpc.org and pancan.org

    続きを読む 一部表示
    32 分
  • The PancChat Podcast -- The Role of Advocacy in Educating the Community
    2025/07/01

    Welcome to the PancChat Podcast! Journalist Alisyn Camerota sits down with Let’s Win CEO Cindy Price Gavin and PanCAN President and CEO Julie Fleshman in the premiere episode of PancChat. Together, they explore the evolution and impact of advocacy in the fight against pancreatic cancer and why the time was right to launch a collaborative podcast between Let’s Win and PanCAN.


    From our nearly nine years as a chat on Twitter/X to increasing federal research funding and improved patient survival rates, this episode explores how advocacy has transformed the landscape. Hear how collaboration, education, and unrelenting dedication are shaping the future of how we communicate about pancreatic cancer.

    続きを読む 一部表示
    25 分